South Africa: Lenacapavir rollout must overcome prevention-pill lessons

Lenacapavir, a twice-yearly HIV prevention injection, faces adoption hurdles in South Africa despite efficacy. Historical experience with oral PrEP shows access, demand generation, and delivery systems are critical. The piece outlines six lessons to ensure the drug reaches high-risk populations, highlighting implementation gaps rather than clinical efficacy.